Overview

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Status:
Completed

Trial end date:
2021-01-29

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS).

Phase:

Phase 3

Details

Lead Sponsor:

Ariad Pharmaceuticals

Treatments:

Crizotinib